Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Bojke

Showing results (41-50 of 84) with videos related to

Pageof 9
Sort By:
Pharmacoeconomics - Open|April 4, 2019
Correction to: Which Costs Matter? Costs Included in Economic Evaluation and their Impact on Decision Uncertainty for Stable Coronary Artery DiseaseJames Lomas, Miqdad Asaria, Laura Bojke, et al.
Age and Ageing|February 27, 2021
Delayed transfers of care for older people: a wider perspectiveSebastian Hinde, Laura Bojke, Gerry Richardson, et al.
Pharmacoeconomics|January 19, 2013
When does NICE recommend the use of health technologies within a programme of evidence development? : a systematic review of NICE guidanceLouise Longworth, Jihee Youn, Laura Bojke, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|March 24, 2016
Extrapolating Survival from Randomized Trials Using External Data: A Review of MethodsChristopher Jackson, John Stevens, Shijie Ren, et al.
Rheumatology (Oxford, England)|August 24, 2011
Modelling the cost-effectiveness of biologic treatments for psoriatic arthritisLaura Bojke, David Epstein, Dawn Craig, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 28, 2015
Unifying Research and Reimbursement Decisions: Case Studies Demonstrating the Sequence of Assessment and Judgments RequiredClaire McKenna, Marta Soares, Karl Claxton, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|December 16, 2021
Modelling decay in effectiveness for evaluation of behaviour change interventions: a tutorial for public health economistsPaolo Candio, Koen B Pouwels, David Meads, et al.
International Journal of Environmental Research and Public Health|November 27, 2024
A Systematic Review of the Impact of Changes to Urban Green Spaces on Health and Education Outcomes, and a Critique of Their Applicability to Inform Economic EvaluationWajeeha Raza, Laura Bojke, Peter A Coventry, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 8, 2016
A Comprehensive Algorithm for Approval of Health Technologies With, Without, or Only in Research: The Key Principles for Informing Coverage DecisionsKarl Claxton, Stephen Palmer, Louise Longworth, et al.
Pharmacoeconomics|January 31, 2012
Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisalHuiqin Yang, Dawn Craig, David Epstein, et al.
Pageof 9

Showing results (41-50 of 84) with videos related to

Sort By:
Pageof 9
Pharmacoeconomics - Open|April 4, 2019
Correction to: Which Costs Matter? Costs Included in Economic Evaluation and their Impact on Decision Uncertainty for Stable Coronary Artery DiseaseJames Lomas, Miqdad Asaria, Laura Bojke, et al.
Age and Ageing|February 27, 2021
Delayed transfers of care for older people: a wider perspectiveSebastian Hinde, Laura Bojke, Gerry Richardson, et al.
Pharmacoeconomics|January 19, 2013
When does NICE recommend the use of health technologies within a programme of evidence development? : a systematic review of NICE guidanceLouise Longworth, Jihee Youn, Laura Bojke, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|March 24, 2016
Extrapolating Survival from Randomized Trials Using External Data: A Review of MethodsChristopher Jackson, John Stevens, Shijie Ren, et al.
Rheumatology (Oxford, England)|August 24, 2011
Modelling the cost-effectiveness of biologic treatments for psoriatic arthritisLaura Bojke, David Epstein, Dawn Craig, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 28, 2015
Unifying Research and Reimbursement Decisions: Case Studies Demonstrating the Sequence of Assessment and Judgments RequiredClaire McKenna, Marta Soares, Karl Claxton, et al.
The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care|December 16, 2021
Modelling decay in effectiveness for evaluation of behaviour change interventions: a tutorial for public health economistsPaolo Candio, Koen B Pouwels, David Meads, et al.
International Journal of Environmental Research and Public Health|November 27, 2024
A Systematic Review of the Impact of Changes to Urban Green Spaces on Health and Education Outcomes, and a Critique of Their Applicability to Inform Economic EvaluationWajeeha Raza, Laura Bojke, Peter A Coventry, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 8, 2016
A Comprehensive Algorithm for Approval of Health Technologies With, Without, or Only in Research: The Key Principles for Informing Coverage DecisionsKarl Claxton, Stephen Palmer, Louise Longworth, et al.
Pharmacoeconomics|January 31, 2012
Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisalHuiqin Yang, Dawn Craig, David Epstein, et al.
Pageof 9